Key result
Gatifloxacin was associated with corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in 4 patients with known risk factors for cardiac toxicity.
Why the study?
Does gatifloxacin cause QT prolongation, torsades de pointes, or ventricular fibrillation in patients with known risk factors?
Does gatifloxacin cause QT prolongation, torsades de pointes, or ventricular fibrillation in patients with known risk factors?
Gatifloxacin can cause severe cardiac toxicity including QT prolongation and torsades de pointes in patients with pre-existing risk factors.
May warrant QT monitoring with gatifloxacin in patients with cardiac risk factors; leaves open causal magnitude without controlled data.
Drugs not commonly considered to be cardioactive agents have been reported to cause prolongation of the corrected QT interval with resultant torsades de pointes or ventricular fibrillation. We report 4 cases of gatifloxacin-associated cardiac toxicity in patients with known risk factors for this adverse event.
No takes yet. Share an insight, caveat, or question.
Bertino et al. (2002) studied this question. Gatifloxacin was associated with corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in 4 patients with known risk factors for cardiac toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: